

Peter Atadja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11742978/publications.pdf>

Version: 2024-02-01

90
papers

10,616
citations

30047

54
h-index

45285

90
g-index

92
all docs

92
docs citations

92
times ranked

11147
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90. <i>Journal of Biological Chemistry</i> , 2005, 280, 26729-26734.	1.6	694
2	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 21360-21365.	3.3	501
3	Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. <i>Cancer Letters</i> , 2009, 280, 233-241.	3.2	358
4	Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. <i>Blood</i> , 2009, 114, 2733-2743.	0.6	336
5	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. <i>Blood</i> , 2005, 105, 1768-1776.	0.6	332
6	Aggresome induction by proteasome inhibitor bortezomib and β -tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. <i>Blood</i> , 2006, 108, 3441-3449.	0.6	328
7	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1 α . <i>Cancer Research</i> , 2006, 66, 8814-8821.	0.4	292
8	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 4500-4510.	3.2	286
9	Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589. <i>Clinical Cancer Research</i> , 2006, 12, 634-642.	3.2	264
10	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. <i>Nature Chemical Biology</i> , 2017, 13, 381-388.	3.9	259
11	Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia. <i>Molecular Cell</i> , 2014, 53, 247-261.	4.5	252
12	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. <i>Cancer Research</i> , 2006, 66, 5781-5789.	0.4	233
13	The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584. <i>Cancer Research</i> , 2004, 64, 6626-6634.	0.4	229
14	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. <i>Blood</i> , 2003, 102, 2615-2622.	0.6	220
15	Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. <i>Cancer Research</i> , 2003, 63, 5126-35.	0.4	218
16	Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells. <i>Cancer Research</i> , 2004, 64, 2580-2589.	0.4	215
17	Role of Acetylation and Extracellular Location of Heat Shock Protein 90 α in Tumor Cell Invasion. <i>Cancer Research</i> , 2008, 68, 4833-4842.	0.4	213
18	Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 971-84.	1.9	191

#	ARTICLE	IF	CITATIONS
19	HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. <i>Blood</i> , 2008, 112, 1886-1893.	0.6	176
20	Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6841-6846.	3.3	167
21	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. <i>Blood</i> , 2009, 114, 5024-5033.	0.6	165
22	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	1.7	144
23	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. <i>Cancer Biology and Therapy</i> , 2007, 6, 64-69.	1.5	143
24	Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2008, 6, 873-883.	1.5	143
25	Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. <i>Blood</i> , 2006, 108, 645-652.	0.6	142
26	Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824. <i>Cancer Research</i> , 2004, 64, 689-695.	0.4	141
27	Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor- α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90. <i>Clinical Cancer Research</i> , 2007, 13, 4882-4890.	3.2	138
28	The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Philadelphia acute lymphoblastic leukemia cells. <i>Blood</i> , 2008, 111, 5093-5100.	0.6	134
29	Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. <i>Nature Communications</i> , 2015, 6, 8651.	5.8	134
30	N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4609-4624.	2.9	129
31	Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3. <i>Clinical Cancer Research</i> , 2004, 10, 4991-4997.	3.2	128
32	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2515-2524.	1.9	117
33	Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3096-3104.	1.9	115
34	Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6663-6673.	3.2	115
35	Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 753-757.	2.9	112
36	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. <i>Blood</i> , 2009, 114, 380-393.	0.6	108

#	ARTICLE	IF	CITATIONS
37	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. <i>Blood</i> , 2014, 123, 1341-1352.	0.6	107
38	Combination Strategy Targeting the Hypoxia Inducible Factor-1 α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2008, 14, 3589-3597.	3.2	105
39	Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3285-3297.	1.9	104
40	Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1311-1319.	1.9	94
41	Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 973-983.	1.9	93
42	IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. <i>Blood</i> , 2010, 115, 2430-2440.	0.6	88
43	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2215-2226.	2.9	86
44	Overexpression of Cyclin D1 Blocks Proliferation of Normal Diploid Fibroblasts. <i>Experimental Cell Research</i> , 1995, 217, 205-216.	1.2	84
45	Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. <i>Cancer Biology and Therapy</i> , 2009, 8, 939-950.	1.5	84
46	Polycomb Target Genes Are Silenced in Multiple Myeloma. <i>PLoS ONE</i> , 2010, 5, e11483.	1.1	81
47	Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. <i>Blood</i> , 2008, 112, 2896-2905.	0.6	80
48	Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. <i>International Journal of Cancer</i> , 2010, 127, 2199-2208.	2.3	79
49	Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 942-952.	1.9	76
50	Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation. <i>Clinical Cancer Research</i> , 2007, 13, 1140-1148.	3.2	75
51	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 70-81.	1.9	74
52	In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with ^3H -Deoxy- ^3H -[18F]Fluorothymidine Positron Emission Tomography. <i>Cancer Research</i> , 2006, 66, 7621-7629.	0.4	68
53	Histone Deacetylase Inhibitors Activate NF- κ B in Human Leukemia Cells through an ATM/NEMO-related Pathway. <i>Journal of Biological Chemistry</i> , 2010, 285, 10064-10077.	1.6	57
54	Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation. <i>Journal of Biological Chemistry</i> , 2011, 286, 38725-38737.	1.6	55

#	ARTICLE	IF	CITATIONS
55	Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4752-4772.	2.9	54
56	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	3.2	53
57	Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. <i>Blood</i> , 2009, 113, 4038-4048.	0.6	50
58	Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2010, 16, 4742-4754.	3.2	49
59	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. <i>Free Radical Biology and Medicine</i> , 2011, 50, 313-322.	1.3	49
60	Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. <i>Haematologica</i> , 2004, 89, 419-26.	1.7	47
61	Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival. <i>Clinical Cancer Research</i> , 2008, 14, 2918-2926.	3.2	46
62	The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. <i>Journal of Pathology</i> , 2009, 218, 467-477.	2.1	46
63	Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. <i>Blood</i> , 2010, 116, 5306-5315.	0.6	46
64	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. <i>Oncotarget</i> , 2012, 3, 1416-1427.	0.8	46
65	Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2012, 18, 6227-6238.	3.2	43
66	Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts. <i>Neoplasia</i> , 2008, 10, 303-313.	2.3	41
67	Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling. <i>Cell Chemical Biology</i> , 2016, 23, 1228-1240.	2.5	41
68	Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6. <i>Radiotherapy and Oncology</i> , 2009, 92, 125-132.	0.3	40
69	Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 337-344.	1.1	40
70	Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. <i>Neuro-Oncology</i> , 2008, 10, 309-319.	0.6	38
71	Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. <i>PLoS ONE</i> , 2017, 12, e0169855.	1.1	36
72	Regulation of transcription factor activity during cellular aging. <i>Biochemistry and Cell Biology</i> , 1996, 74, 523-534.	0.9	33

#	ARTICLE	IF	CITATIONS
73	A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL. <i>Journal of Thoracic Oncology</i> , 2009, 4, 149-160.	0.5	32
74	Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2952-2963.	2.9	32
75	Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. <i>Oncotarget</i> , 2017, 8, 85085-85101.	0.8	32
76	ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth. <i>PLoS ONE</i> , 2012, 7, e43671.	1.1	30
77	Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain. <i>SLAS Discovery</i> , 2018, 23, 930-940.	1.4	29
78	Potential of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1772-1785.	1.9	28
79	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4909-4912.	1.0	26
80	Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5317-5333.	2.9	24
81	Molecular and Cellular Basis for the Anti-Proliferative Effects of the HDAC Inhibitor LAQ824. <i>Novartis Foundation Symposium</i> , 2008, , 249-268.	1.2	23
82	Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression. <i>PLoS ONE</i> , 2011, 6, e27178.	1.1	16
83	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. <i>Clinical Cancer Research</i> , 2012, 18, 2230-2239.	3.2	16
84	Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. <i>Novartis Foundation Symposium</i> , 2004, 259, 249-66; discussion 266-8, 285-8.	1.2	16
85	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 2.	1.8	13
86	Biocatalytic Synthesis and Structure Elucidation of Cyclized Metabolites of the Deacetylase Inhibitor Panobinostat (LBH589). <i>Drug Metabolism and Disposition</i> , 2012, 40, 1041-1050.	1.7	12
87	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011, 128, 2735-2747.	2.3	11
88	HDAC Inhibitors. , 2006, , 315-332.		4
89	Efficacy of Panobinostat (LBH589) in CTCL Cell Lines and a Murine Xenograft Model: Defining Molecular Pathways of Panobinostat Activity in CTCL. <i>Blood</i> , 2007, 110, 1375-1375.	0.6	3
90	Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma. <i>Blood</i> , 2007, 110, 1510-1510.	0.6	3